Protein Summary
Cooperates with LY96 to mediate the innate immune response to bacterial lipoproteins and other microbial cell wall components. Cooperates with TLR1 or TLR6 to mediate the innate immune response to bacterial lipoproteins or lipopeptides (PubMed:21078852, PubMed:17889651). Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. May also activate immune cells and promote apoptosis in response to the lipid moiety of lipoproteins (PubMed:10426995, PubMed:10426996). Recognizes mycoplasmal macrophage-activating lipopeptide-2kD (MALP-2), soluble tuberculosis factor (STF), phenol-soluble modulin (PSM) and B.burgdorferi outer surface protein A lipoprotein (OspA-L) cooperatively with TLR6 (PubMed:11441107). Stimulation of monocytes in vitro with M.tuberculosis PstS1 induces p38 MAPK and ERK1/2 activation primarily via this receptor, but also partially via TLR4 (PubMed:16622205). MAPK activation in response to bacterial peptidoglycan also occur ...more
- ENST00000260010
- ENSP00000260010
- ENSG00000137462
- ENST00000642580
- ENSP00000495339
- ENST00000642700
- ENSP00000494425
- ENST00000644308
- ENSP00000496321
- TIL4
- TIL4
- CD282
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
biological process | 1 | ||
biological term | 1 | ||
virus perturbation | 1 | ||
protein domain | 0.85 | ||
disease | 0.84 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 5516.89 (req: < 5)
Gene RIFs: 1397 (req: <= 3)
Antibodies: 1225 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 5516.89 (req: >= 5)
Gene RIFs: 1397 (req: > 3)
Antibodies: 1225 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 68
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 64
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0